PharmaCyte Biotech Research Identifies Enzyme Activity for Cannabinoid Cancer Therapy

- October 17th, 2017

PharmaCyte Biotech announced its research partner, the University of Northern Colorado, identified an organism whose genome contains the genetic code for the production of an enzyme capable of activating a cannabinoid prodrug into its active cancer-killing form.

PharmaCyte Biotech (OTCQB:PMCB) announced its research partner, the University of Northern Colorado (UNC), identified an organism whose genome contains the genetic code for the production of an enzyme capable of activating a cannabinoid prodrug into its active cancer-killing form.
As quoted in the press release:

“We are pleased that UNC has taken us one step closer to developing cannabinoid-based therapies to combat cancer utilizing our proprietary Cell-in-a-Box live-cell encapsulation technology,” commented PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner. “PharmaCyte’s innovative Cannabis Program has established PharmaCyte as a serious player in the medical Cannabis sector, and we are exploring additional strategic relationships to advance product development and commercialization.”
PharmaCyte’s Cannabis Program has had two primary areas of focus. The first is confirming the anti-cancer activity of cannabinoids (constituents of the Cannabis plant), such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Click here to read the full press release.

Source: www.businesswire.com

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply